What changed
Penumbra reported Q3 FY26 revenue of $410M, up 15.6% YoY, with net income of $42M. Top-line growth was driven by global thrombectomy revenue of $279.2M (+18.1% YoY), including U.S. VTE revenue up 26.0%, while global embolization and access revenue rose 10.8% to $131.0M. Gross margin expanded 0.5 points to 68.3%. The company will not provide FY26 guidance or host a call given the pending acquisition by Boston Scientific.
Why it matters
Penumbra reported Q3 FY26 revenue of $410M, up 15.6% YoY, with net income of $42M. Top-line growth was driven by global thrombectomy revenue of $279.2M (+18.1% YoY), including U.S. VTE revenue up 26.0